Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

Completed · Phase 3 · Has a placebo group

Conditions studied: Germ Cell Tumors

In brief

Aprepitant is currently approved for prophylaxis of acute and delayed CINV for highly emetogenic chemotherapy regimens, including cisplatin; however, it has not yet been studied in multiple-day chemotherapy treatment programs. This study will compare the addition of aprepitant compared to placebo administered on days 3,4,5 of chemotherapy administration for acute CINV prophylaxis with standard antiemetic prophylaxis and days 6 and 7 for delayed CINV prophylaxis in a double-blind, randomized, crossover study design.

Key facts

Study ID

NCT00572572

Run by

Hoosier Cancer Research Network

People needed

69

Starts

2007-12-01

Expected to finish

2011-02-01

Last updated by the study team

2016-04-06

Who can join

Age: 15 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologic, serologic or clinical evidence of germ cell tumor.
• Patients scheduled to receive a 5 day fractionated cisplatin-based combination chemotherapy on permitted regimens
• Prior chemotherapy is allowed. Patients will be stratified based on previous treatment.
• Male patients 15 years of age or older at time of registration.
• Patient will provide written informed consent and authorization to release personal health information.

You may not qualify if…

• No known history of anticipatory nausea or vomiting.
• No use of another antiemetic agent within 72 hours prior to beginning chemotherapy.
• No known central nervous system (CNS) metastasis.
• No known hypersensitivity to any component of study regimen.
• No concurrent participation in a clinical trial which involves another investigational agent.
• No use of warfarin while on study.
• No use of agents expected to induce the metabolism of aprepitant which include: Rifampin, Rifabutin, Phenytoin, Carbamazepine, and barbiturates.
• No use of agents which may impair metabolism of aprepitant which include: Cisapride, macrolide antibiotics (Erythromycin, Clarithromycin, Azithromycin), azole antifungal agents (Ketoconazole, Itraconazole, Voriconazole, Fluconazole), Amifostine, Nelfinavir and Ritonavir.

Where it is running

• Indiana University Simon Cancer Center — Indianapolis, Indiana, United States
• Medical Consultants, P.C. — Muncie, Indiana, United States
• Siteman Cancer Center — St Louis, Missouri, United States
• Providence Portland Medical Center — Portland, Oregon, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Froedtert/Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.